Summary
Pneumonia is a potentially serious infection and an important cause of mortality in previously healthy adults. Pulmonary defence mechanisms usually prevent the development of infection, but a defect in host defences, a large inoculum or a particularly virulent pathogen may overcome these. Major pathogens associated with community-acquired pneumonia include Streptococcus pneumoniae, Haemophilus influenza and Mycoplasma pneumoniae, and mixed infections may also occur. Standard treatment is with ampicillin derivatives or erythromycin. Roxithromycin is a new macrolide antibiotic with activity against many of the pathogens associated with community-acquired pneumonia and, in the 1990s, may become an antibiotic treatment of choice in patients presenting with the signs and symptoms of pneumonia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anon. Antibiotics for community-acquired pneumonia in adults. Drug and Therapeutics Bulletin 26: 13–16, 1988
Bazet MC, Blanc F, Chumdermpadetsuk S, Fiessinger S, Kafetzis D, et al. Roxithromycin in the treatment of paediatric infections. British Journal of Clinical Practice 42(Suppl. 55): 117–118, 1988
Bruckner O, Trautmann M, Kemmerich B. Roxithromycin (ROX) compared to a new cephalosporin cefixime (CEF) and cipro-floxacin (CIP) in purulent chest disease and pneumonia. 16th International Congress of Chemotherapy, Jerusalem, June 11–16, 1989
Donowitz GR, Mandell GL. Acute pneumonia. In Mandell GL, Douglas Jr RG, Bennett JE (Eds) Principles and practice of infectious diseases, 3rd ed., pp. 540–555, Churchill Livingstone, New York, 1990
Fernandez-MacLoughlin GJ, Lanoël JL, Stamboulian D, Sarachian B. Roxithromycin in the treatment of atypical pneumonia. British Journal of Clinical Practice 42(Suppl. 55): 92–93, 1988
Finch RG. Epidemiological features and chemotherapy of community-acquired respiratory tract infections. Journal of Antimicrobial Chemotherapy 26(Suppl. E): 53–61, 1990
Gentry LO. Roxithromycin, a new macrolide antibiotic, in the treatment of infections in the lower respiratory tract: an overview. Journal of Antimicrobial Chemotherapy 20(Suppl. B): 145–152, 1987
Lachat JM, Anex JF, Regamey C. Roxithromycin (RU 28965), un nouveau macrolide efficace dans les infections pulmonaires. Schweizerische Medizinische Wochenschrift 116: 1739–1741, 1986
Matsumoto F, Hara K. Multicentre clinical studies of roxithromycin in respiratory, otorhinolaryngological, skin and dental infections, and chlamydial sexually transmitted diseases. 15th International Congress of Chemotherapy, Istanbul, July 19–24, 1987
Rahlwes M, Wagner J, Schuster L, Berntsson E, Ruckdeschel G, et al. Prospective study of the aetiology of community-acquired pneumonia and comparison of amoxycillin and roxithromycin therapy. 15th International Congress of Chemotherapy, Istanbul, July 19–24, 1987
Steiner G, Huber W, Wutz R, Neumann M, Janistyn W. et al. Roxithromycin: a safe and efficacious antibiotic in the treatment of lower respiratory tract infections. British Journal of Clinical Practice 42(Suppl. 55): 96–97, 1988
Young RA, Gonzalez JP, Sorkin EM. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 37: 8–41, 1989
Zeluff BJ, Lowe P, Koornhof H, Gentry LO. A comparative study of a new macrolide antibiotic (RU-965) and cephradine in mild to moderate pneumococcal pneumonia. Interscience Congress of Antimicrobial Agents and Chemotherapy, New Orleans, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de la Cabada, F.J. Community-Acquired Pneumonia. Drug Invest 3 (Suppl 3), 7–10 (1991). https://doi.org/10.1007/BF03258328
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258328